These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 19337444)

  • 41. High-dose intravenous pamidronate for metastatic bone pain.
    Purohit OP; Anthony C; Radstone CR; Owen J; Coleman RE
    Br J Cancer; 1994 Sep; 70(3):554-8. PubMed ID: 8080746
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Treatment of bone metastases from breast cancer and myeloma with pamidronate.
    Thiébaud D; Leyvraz S; von Fliedner V; Perey L; Cornu P; Thiébaud S; Burckhardt P
    Eur J Cancer; 1991; 27(1):37-41. PubMed ID: 1826438
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Economic evaluation of zoledronic acid versus pamidronate for the prevention of skeletal-related events in metastatic breast cancer and multiple myeloma.
    Reed SD; Radeva JI; Glendenning GA; Coleman RE; Schulman KA
    Am J Clin Oncol; 2005 Feb; 28(1):8-16. PubMed ID: 15685028
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Dramatic pain relief and resolution of bone inflammation following pamidronate in 9 pediatric patients with persistent chronic recurrent multifocal osteomyelitis (CRMO).
    Miettunen PM; Wei X; Kaura D; Reslan WA; Aguirre AN; Kellner JD
    Pediatr Rheumatol Online J; 2009 Jan; 7():2. PubMed ID: 19138427
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Evaluation and comparison of safety, convenience and cost of administering intravenous pamidronate infusions to children in the home and ambulatory care settings.
    Rush ET; DeHaai K; Kreikemeier RM; Lutz RE
    J Pediatr Endocrinol Metab; 2012; 25(5-6):493-7. PubMed ID: 22876544
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Management of bone metastases in breast cancer.
    Lipton A
    Curr Treat Options Oncol; 2005 Mar; 6(2):161-71. PubMed ID: 15717997
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Pamidronate in the treatment of tumor-associated hypercalcemia].
    Pecherstorfer M; Janisch S; Marosi C; Wogritsch C; Bosse C; Schratzberger W; Gerber E; Fortelny A; Lenzhofer R; Rainer H
    Klin Wochenschr; 1991 Oct; 69(15):690-5. PubMed ID: 1795492
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate.
    Markowitz GS; Appel GB; Fine PL; Fenves AZ; Loon NR; Jagannath S; Kuhn JA; Dratch AD; D'Agati VD
    J Am Soc Nephrol; 2001 Jun; 12(6):1164-1172. PubMed ID: 11373339
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Safety and convenience of a 15-minute infusion of zoledronic acid.
    Berenson J; Hirschberg R
    Oncologist; 2004; 9(3):319-29. PubMed ID: 15169987
    [TBL] [Abstract][Full Text] [Related]  

  • 50. One-shot high-dose pamidronate disodium (APD): effective, simple treatment for hypercalcaemia in haematological malignancy.
    Sawyer N; Newstead C; Drummond A; Newland A; Cunningham J
    Clin Lab Haematol; 1989; 11(3):179-84. PubMed ID: 2591149
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy.
    Purohit OP; Radstone CR; Anthony C; Kanis JA; Coleman RE
    Br J Cancer; 1995 Nov; 72(5):1289-93. PubMed ID: 7577484
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Administration of pamidronate helps prevent immediate postparathyroidectomy hungry bone syndrome.
    Davenport A; Stearns MP
    Nephrology (Carlton); 2007 Aug; 12(4):386-90. PubMed ID: 17635755
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical trials of bisphosphonates in multiple myeloma.
    Mahindra A; Pozzi S; Raje N
    Clin Adv Hematol Oncol; 2012 Sep; 10(9):582-7. PubMed ID: 23073123
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Severe hypercalcemia associated with Williams syndrome successfully treated with pamidronate infusion therapy.
    Sangun O; Dundar BN; Erdogan E
    J Pediatr Endocrinol Metab; 2011; 24(1-2):69-70. PubMed ID: 21528818
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evaluation of a Modified Pamidronate Protocol for the Treatment of Osteogenesis Imperfecta.
    Palomo T; Andrade MC; Peters BS; Reis FA; Carvalhaes JT; Glorieux FH; Rauch F; Lazaretti-Castro M
    Calcif Tissue Int; 2016 Jan; 98(1):42-8. PubMed ID: 26387692
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Changes in calcium homoeostasis in patients undergoing liver transplantation: effects of a single infusion of pamidronate administered pre-operatively.
    Bishop NJ; Ninkovic M; Alexander GJ; Holmes SD; Milligan T; Price C; Compston JE
    Clin Sci (Lond); 1999 Aug; 97(2):157-63. PubMed ID: 10409470
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy and safety of intravenous bisphosphonates for patients with breast cancer metastatic to bone: a review of randomized, double-blind, phase III trials.
    Gordon DH
    Clin Breast Cancer; 2005 Jun; 6(2):125-31. PubMed ID: 16001990
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma.
    Kunzmann V; Bauer E; Feurle J; Weissinger F; Tony HP; Wilhelm M
    Blood; 2000 Jul; 96(2):384-92. PubMed ID: 10887096
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Bisphosphonates for breast cancer.
    Pavlakis N; Stockler M
    Cochrane Database Syst Rev; 2002; (1):CD003474. PubMed ID: 11869664
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacokinetics of pamidronate disodium in patients with cancer with normal or impaired renal function.
    Berenson JR; Rosen L; Vescio R; Lau HS; Woo M; Sioufi A; Kowalski MO; Knight RD; Seaman JJ
    J Clin Pharmacol; 1997 Apr; 37(4):285-90. PubMed ID: 9115053
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.